Radiation and immune drugs join forces against tough cancers
NCT ID NCT02639026
First seen Jan 05, 2026 · Last updated May 19, 2026 · Updated 22 times
Summary
This early-phase trial tested whether combining a special type of radiation (hypofractionated radiotherapy) with two immunotherapy drugs (MEDI4736 and tremelimumab) is safe and tolerable for people with advanced melanoma, lung, breast, or pancreatic cancer that has spread. The study included 53 participants and focused on tracking side effects. The goal was to find the best way to combine these treatments to potentially help the immune system fight cancer more effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.